|
WO2021044420A1
|
|
Liquid compositions comprising a levodopa amino acid conjugate and uses thereof
|
|
US2020368448A1
|
|
Syringe filling adjustment devices and methods
|
|
WO2020178810A1
|
|
Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
|
|
WO2020035853A1
|
|
Process for preparing purified levodopamide free base
|
|
WO2019038639A1
|
|
Crystalline levodopa amide free base and methods of making and using same
|
|
WO2019038638A1
|
|
Process for preparing purified levodopa amide
|
|
WO2019038637A1
|
|
Crystalline salt forms of levodopa amide and methods of making and using same
|
|
CN111467608A
|
|
Device for subcutaneous delivery of fluid drugs
|
|
WO2018154447A1
|
|
Dopa decarboxylase inhibitor compositions
|
|
US2017157079A1
|
|
DOPA decarboxylase inhibitor compositions
|
|
AU2016358511A1
|
|
Pharmaceutical compositions comprising levodopa amide and uses thereof
|
|
IL243818D0
|
|
Stable pharmaceutical compositions comprising arginine and carbidopa
|
|
WO2016103262A2
|
|
Crystal forms of apomorphine and uses thereof
|
|
US2018140610A1
|
|
Opipramol patch
|
|
IL241482D0
|
|
Method for treatment of parkinson's disease
|
|
AU2015228369A1
|
|
DOPA decarboxylase inhibitor compositions
|
|
SG10201911731YA
|
|
Method for treatment of parkinson's disease
|
|
AU2013273138A1
|
|
Compositions comprising apomorphine and organic acids and uses thereof
|
|
US2013253056A1
|
|
Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
|
|
NZ610911A
|
|
Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
|
